Mao Y, Gao Z, Sun Y, Shao C, et al. Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma. BMC Cancer 2025;25:1328.
PMID: 40826031